References
- Miller PD. Management of severe osteoporosis. Expert Opin Pharmacother. 2016;17:473–488.
- Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121–145.
- Almalki SG, Agrawal DK. Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation. 2016;92:41–51.
- Katsimbri P. The biology of normal bone remodelling. Eur J Cancer Care. 2017;26:e12740.
- Golub EE, Boesze-Battaglia K. The role of alkaline phosphatase in mineralization. Curr Opin Orthop. 2007;18:444–448.
- Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–1287.
- Hauser AS, Misty A, Mathias RA, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16:829–842.
- Hershfinkel M. The zinc sensing receptor, ZnR/GPR39, in health and disease. Int J Mol Sci. 2018;19:439.
- Peukert S, Hughes R, Nunez J, et al. Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists. ACS Med Chem Lett. 2014;5:1114–1118.
- Shimizu Y, Koyama R, Kawamoto T. Rho kinase-dependent desensitization of GPR39; a unique mechanism of GPCR downregulation. Biochem Pharmacol. 2017;140:105–114.
- Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011;11:12
- Kim SS, Choi JM, Kim JW, et al. cAMP induces neuronal differentiation of mesenchymal stem cells via activation of extracellular signal-regulated kinase/MAPK. Neuroreport. 2005;16:1357–1361.
- Abramovitch-Dahan C, Asraf H, Bogdanovic M, et al. Amyloid β attenuates metabotropic zinc sensing receptor, mZnR/GPR39, dependent Ca2+ , ERK1/2 and Clusterin signaling in neurons. J Neurochem. 2016;139:221–233.
- Kanazawa I, Yamaguchi T, Yano S, et al. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab. 2009;296:E139–46.
- Młyniec K, Starowicz G, Gaweł M, et al. Potential antidepressant-like properties of the TC G-1008, a GPR39 (zinc receptor) agonist. J Affect Disord. 2016;201:179–184.
- Sudo H, Kodama HA, Amagai Y, et al. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol. 1983;96:191–198.
- Saura M, Tarin C, Zaragoza C. Recent insights into the implication of nitric oxide in osteoblast differentiation and proliferation during bone development. Scientific World J. 2010;10:624–632.
- Kalyanaraman H, Schall N, Pilz RB. Nitric oxide and cyclic GMP functions in bone. Nitric Oxide. 2018;76:62–70.
- Chen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res. 2009;104:496–505.
- Jang WG, Kim EJ, Lee KN, et al. AMP-activated protein kinase (AMPK) positively regulates osteoblast differentiation via induction of Dlx5-dependent Runx2 expression in MC3T3E1 cells. Biochem Biophys Res Commun. 2011;404:1004–1009.
- Jovanovic M, Schmid FN, Guterman-Ram G, et al. Perturbed bone composition and integrity with disorganized osteoblast function in zinc receptor/Gpr39-deficient mice. FASEB J. 2018;32:2507–2518.
- Luo J, Zhou W, Zhou X, et al. Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development. 2009;136:2747–2756.